Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 3/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | ARG1 | P05089 | 1/20 | 0.30 |
| ▸ | ARG2 | P78540 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4347961 | 0.94 | LMNA (0.33) | PIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL4203206 | 0.84 | PARP1 (0.36) | — | |
| SCHEMBL4194787 | 0.84 | PARP1 (0.39) | — | |
| SCHEMBL4205217 | 0.82 | PARP1 (0.41) | — | |
| SCHEMBL4199475 | 0.81 | L3MBTL1 (0.38) | PIK3CDPIK3R1PIK3CAPIK3CBCA2 | |
| SCHEMBL4201719 | 0.79 | MEN1 (0.47) | PIK3CDPIK3R1PIK3CAPIK3CBCA2 | |
| SCHEMBL4357843 | 0.78 | ALOX15 (0.33) | — | |
| SCHEMBL4207922 | 0.77 | CARM1 (0.40) | CA2 | |
| SCHEMBL27521755 | 0.75 | KDM1A (0.43) | KDM1A | |
| SCHEMBL4197542 | 0.74 | LOX (0.40) | PIK3CDKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275567-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| EP-2032559-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | AstraZeneca AB (SE) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007138268-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275567-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | CCNI, MKI67, CDK2 | PIK3CD 533/4885PIK3R1 1738/4885PIK3CA 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.